Anti-CD40L antagonist

Drug Profile

Anti-CD40L antagonist

Alternative Names: Anti-CD40 ligand antagonist

Latest Information Update: 09 Nov 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ImmuNext
  • Class Antibodies; Bispecific antibodies
  • Mechanism of Action CD40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Inflammatory bowel diseases; Lupus vulgaris; Multiple sclerosis

Most Recent Events

  • 25 Oct 2016 Preclinical trials in Autoimmune disorders in USA (Parenteral)
  • 25 Oct 2016 Preclinical trials in Inflammatory bowel disease in USA (Parenteral)
  • 25 Oct 2016 Preclinical trials in Lupus in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top